Author:
Wibmer Thomas,Berghmans Thierry,Kropf-Sanchen Cornelia,Lafitte Jean-Jacques,Rüdiger Stefan,Paesmans Marianne,Blanta Ioanna,Scherpereel Arnaud,Stoiber Kathrin M.,Rottbauer Wolfgang,Sculier Jean-Paul,Schumann Christian
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference35 articles.
1. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA (2010) Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28:4769–4777
2. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703
3. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246
4. Pircher A, Ulsperger E, Hack R, Jamnig H, Pall G, Zelger B, Sterlacci W, Hilbe W, Fiegl M (2011) Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer. Anticancer Res 31:2949–2955
5. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C (2010) Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 78:249–258
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献